Browse the corpus

Atenolol is a second-generation β-1–selective adrenergic antagonist that helps lower the heart rate and blood pressure of patients while also decreasing myocardial contractility. Atenolol is approved by the U.S. Food and Drug Administration (FDA) for treating hypertension, angina pectoris, and acute myocardial infarction. Off-label uses of atenolol include the treatment of arrhythmias, migraine prophylaxis, paroxysmal supraventricular tachycardia, alcohol withdrawal, thyrotoxicosis, and prophylaxis against secondary myocardial infarction. Atenolol is an alternative to propranolol in the management of infantile hemangiomas. The mechanistic actions of atenolol are complemented by several cardiovascular drugs when managing cardiac emergencies. This activity provides a comprehensive overview of atenolol, covering its indications, mechanism of action, safe administration, adverse effects, contraindications, monitoring, and toxicity. This activity also highlights the role of an interprofessional team in treating medical conditions using atenolol. Patient outcomes are optimized when this medication is utilized by a team of primary care, emergency medicine, and consulting specialists. Objectives: Identify the FDA-approved indications and off-label uses for atenolol, including hypertension, angina, and acute myocardial infarction. Screen patients for asthma, bronchospasm, or obstructive airway diseases to assess the use of atenolol or consider alternative therapies. Assess patients for adverse drug reactions and recognize potential complications, such as masked symptoms of hypoglycemia and thyrotoxicosis. Collaborate within the interprofessional healthcare team to coordinate comprehensive care for patients using atenolol, ensuring regular renal function, heart rate, and blood pressure monitoring. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose Symptoms of atenolol toxicity may include bradycardia, lethargy, hypotension, respiratory drive disorders, hypothermia, hypoglycemia, and seizures. Management of Overdose The treatment for β-blocker toxicity is primarily supportive. If administered orally, any unabsorbed drug can be removed by gastric lavage or activated charcoal (within 1 to 2 hours). Hemodialysis is effective in eliminating atenolol from the general systemic circulation.[44] Inotropes and chronotropes, such as IV epinephrine and atropine, are recommended for treating severe bradycardia. Usually, atropine is administered as a 0.5-mg IV or intraosseous bolus and may be repeated every 3 to 5 minutes, up to a total dose of 3 mg. A transvenous cardiac pacemaker may also be utilized in refractory cases or for treating second- or third-degree heart block. A titrated glucagon bolus at a dose of 50 mcg/kg can improve myocardial contractility and atrioventricular conduction and increase heart rate in patients. Continuous blood pressure monitoring is imperative, and vasopressors such as norepinephrine (levarterenol) may be considered in hypotension. A β-2 agonist such as aminophylline or isoproterenol may alleviate symptoms for patients with bronchospasm. In cases refractory to the standard treatment, high-dose insulin euglycemic therapy, initiated with a 1 unit/kg bolus followed by a 1 unit/kg/h drip, may be considered to manage overdose under the guidance of a toxicologist.[45] Lignocaine can be used in the management of arrhythmias resulting from β-blocker toxicity. Veno-arterial extracorporeal membrane oxygenation is also associated with reduced mortality.[46] For asymptomatic β-1-blocker overdoses, monitoring the patient for at least 6 hours is recommended.[47]

Beta-1-selective adrenergic antagonists, such as atenolol, have widespread use for the treatment of hypertension, angina, and myocardial infarction. Despite not being the first-line treatment in hypertensive patients without compelling indications, AHA demonstrates that β-blockers are commonly utilized as initial pharmacological therapy for hypertension in clinical practice.[48] An interprofessional healthcare team, including clinicians (MDs, DOs, NPs, and PAs), nurses, and pharmacists, must comprehensively understand the indications, adverse drug reactions, and contraindications associated with atenolol. Nurses responsible for administering atenolol should actively monitor for adverse drug reactions and be aware that the drug's effects may mask the symptoms of hypoglycemia and thyrotoxicosis. Nursing staff can provide counseling on medicine administration, verify patient adherence, assess the regimen's effectiveness during follow-up visits, and communicate any concerns to the clinician. Pharmacists should verify dosing based on individual patient parameters and check for potential interactions that could alter therapeutic results. All members of the interprofessional team must maintain accurate and updated records. If any issues are identified, immediate communication with the prescriber is essential to convey concerns and facilitate potential modifications to the therapy. The interprofessional healthcare team overseeing the patient's care should consistently monitor renal function, heart rate, and blood pressure. This collaborative approach contributes to therapeutic success and ensures optimal outcomes for patients using atenolol. In a pragmatic randomized controlled trial, a team-based care intervention involving collaboration among clinicians, pharmacists, and nurses was implemented for patients with uncontrolled hypertension. The findings demonstrated that this interprofessional approach had the potential to decrease long-term systolic blood pressure in individuals with uncontrolled hypertension receiving antihypertensive therapy, including β-blockers.[49]